Download PDF

1. Company Snapshot

1.a. Company Description

Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally.Its infection prevention solutions reduce the risk of healthcare associated infections and the use of antibiotics.The company's products portfolio of urinary catheters, endotracheal tubes, and central venous catheters reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream.


Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter and BIP Endotracheal Tube, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention.The company's products also include Bactiguard Wound Care and Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for acute, chronic, and infected wounds; surgical sutures comprise non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement used in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi.In addition, it offers ZNN Bactiguard, an orthopedic trauma implants with infection prevention technology; and Aniocyn, a wound and skin care products for dogs, cats, horses, and other pets.


Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.

Show Full description

1.b. Last Insights on BACTI

Have nothing to say about that one ...

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.54%)

6. Segments

Recurring License (Commercial Phase)

Expected Growth: 8%

Strong demand for infection prevention solutions, increasing adoption of urinary catheters with built-in infection protection, and expansion into new geographies drive the 8% growth in Recurring License revenue for Bactiguard Holding AB (publ) in the Commercial Phase.

Bactiguard Infection Protection Products

Expected Growth: 12%

Bactiguard's 12% growth is driven by increasing demand for infection prevention products, particularly in emerging markets. Growing awareness of healthcare-associated infections, advancements in medical technology, and expanding distribution networks contribute to the company's growth. Additionally, strategic partnerships and product innovations, such as the Endoluminal technology, further boost sales.

Non-recurring License (Collaboration Phase)

Expected Growth: 6%

Bactiguard Holding AB's Non-recurring License growth is driven by increasing demand for infection prevention solutions, strategic partnerships, and expansion into new markets. The collaboration phase has accelerated growth, with a 6% increase attributed to successful clinical trials, regulatory approvals, and a growing pipeline of potential customers.

7. Detailed Products

Bactiguard Infection Protection

A urinary catheter that reduces the risk of catheter-associated urinary tract infections (CAUTI) by preventing bacterial growth and biofilm formation on the catheter surface.

Bactiguard Endoluminal

A balloon expandable stent with an anti-infective coating that prevents bacterial growth and biofilm formation, reducing the risk of stent-related infections.

Bactiguard Wound Care

A range of wound care products, including dressings and gel pads, that incorporate Bactiguard's proprietary anti-infective technology to promote wound healing and prevent infection.

Bactiguard Orthopedic Implants

Orthopedic implants, such as hip and knee replacements, that incorporate Bactiguard's anti-infective technology to reduce the risk of implant-related infections.

8. Bactiguard Holding AB (publ)'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Bactiguard Holding AB (publ) is medium due to the presence of alternative infection prevention solutions.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Bactiguard's products and the lack of alternative suppliers.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium due to the presence of multiple suppliers for raw materials and components.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the medical technology industry, including regulatory hurdles and high research and development costs.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established competitors in the infection prevention market, leading to a competitive pricing environment.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 39.76%
Debt Cost 3.95%
Equity Weight 60.24%
Equity Cost 2.88%
WACC 3.30%
Leverage 66.00%

11. Quality Control: Bactiguard Holding AB (publ) passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Medartis

A-Score: 3.9/10

Value: 3.0

Growth: 5.0

Quality: 4.5

Yield: 0.0

Momentum: 8.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
IceCure Medical

A-Score: 3.6/10

Value: 6.0

Growth: 2.8

Quality: 3.4

Yield: 0.0

Momentum: 9.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Euroapi

A-Score: 3.6/10

Value: 9.8

Growth: 3.3

Quality: 2.6

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Stratec

A-Score: 3.0/10

Value: 5.4

Growth: 3.4

Quality: 4.4

Yield: 3.1

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Nano-X Imaging

A-Score: 2.8/10

Value: 7.2

Growth: 4.7

Quality: 3.6

Yield: 0.0

Momentum: 1.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Bactiguard Holding

A-Score: 2.0/10

Value: 4.0

Growth: 4.8

Quality: 3.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

16.8$

Current Price

16.8$

Potential

-0.00%

Expected Cash-Flows